Personalized Medicine in Acromegaly : The ACROFAST Study
Marques-Pamies, Montserrat (Hospital Municipal de Badalona)
Gil, Joan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Sampedro-Nuñez, Miguel (Hospital Universitario de la Princesa (Madrid))
Valassi, Elena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Biagetti, Betina (Hospital Universitari Vall d'Hebron)
Giménez-Palop, Olga (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Hernández García, Marta (Hospital Universitari Arnau de Vilanova)
Martínez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Carrato, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Villar-Taibo, Rocío (Hospital Clínico Universitario (Santiago de Compostela, Galícia))
Araujo-Castro, Marta (Hospital Universitario Ramón y Cajal (Madrid))
Blanco, Concepción (Hospital Universitario Príncipe de Asturias (Alcalá de Henares, Madrid))
Simón-Muela, Inmaculada (Institut d'Investigació Biomèdica de Bellvitge)
Simó-Servat, Andreu (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Xifra, Gemma (Hospital Universitari de Girona Doctor Josep Trueta)
Vázquez, Federico (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Pavón, Isabel (Hospital Universitario de Getafe (Madrid))
Rosado, José Antonio (Hospital Universitario de Getafe (Madrid))
García-Centeno, Rogelio (Hospital General Universitario Gregorio Marañón)
Zavala, Roxana (Hospital Universitari Joan XXIII de Tarragona)
Hanzu, Felicia A. (Hospital Clínic i Provincial de Barcelona)
Mora, Mireia (Hospital Clínic i Provincial de Barcelona)
Aulinas, Anna (Institut de Recerca Sant Pau)
Vilarrasa, Nuria (Institut d'Investigació Biomèdica de Bellvitge)
Librizzi, Soledad (Hospital 12 de Octubre (Madrid))
Calatayud, María (Hospital 12 de Octubre (Madrid))
de Miguel, Paz (Hospital Universitario Clínico San Carlos (Madrid))
Álvarez-Escolá, Cristina (Hospital Universitario La Paz (Madrid))
Picó Alfonso, Antonio M. (Hospital General Universitario Dr. Balmis de Alicante)
Salinas, Isabel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Fajardo-Montañana, Carmen (Hospital Universitari de la Ribera (València))
Cámara, Rosa (Hospital Universitari i Politècnic La Fe (València))
Bernabeu Morón, Ignacio (Hospital Clínico Universitario (Santiago de Compostela, Galícia))
Jordà, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Webb, Susan 1952- (Universitat Autònoma de Barcelona. Departament de Medicina)
Marazuela, Mónica (Hospital Universitario de la Princesa (Madrid))
Puig Domingo, Manuel (Universitat Autònoma de Barcelona. Departament de Medicina)

Additional title:	Medicina Personalizada en Acromegalia : Estudio ACROFAST
Imprint:	The Endocrine Society, 2024
Description:	11 pàg.
Abstract:	Context: Medical treatment of acromegaly is currently performed through a trial-and-error approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs, with an effectiveness of about 50%, and subsequent drugs are indicated through clinical judgment. Some biomarkers can predict fgSRLs response. Objective:Here we report the results of the ACROFAST study, a clinical trial in which a protocol based on predictive biomarkers of fgSRLs was evaluated. Methods: This was a prospective trial (21 university hospitals) comparing the effectiveness and time-to-control of 2 treatment protocols during 12 months: (A) a personalized protocol in which the first options were fgSRLs as monotherapy or in combination with pegvisomant, or pegvisomant as monotherapy depending on the short acute octreotide test (sAOT) results, tumor T2 magnetic resonance (MRI) signal or immunostaining for E-cadherin; and (B) a control group with treatment always started by fgSRLs and the other drugs included after demonstrating inadequate control. Results:Eighty-five patients participated; 45 in the personalized and 40 in the control group. More patients in the personalized protocol achieved hormonal control compared to those in the control group (78% vs 53%, P < . 05). Survival analysis revealed a hazard ratio for achieving hormonal control adjusted by age and sex of 2. 53 (CI, 1. 30-4. 80). Patients from the personalized arm were controlled in a shorter period of time (P = . 01). Conclusion:Personalized medicine is feasible using a relatively simple protocol, and it allows a higher number of patients to achieve control in a shorter period of time.
Grants:	Ministerio de Economía y Competitividad PMP15/00027 Instituto de Salud Carlos III PMP22/00021
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Acromegaly ; Medical treatment ; Personalized therapy ; First-generation somatostatin receptor ligands ; Therapeutic response prediction ; Clinical trial
Published in:	The journal of clinical endocrinology & metabolism, (june 2024) , ISSN 1945-7197

DOI: 10.1210/clinem/dgae444
PMID: 38943661

11 p, 543.8 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles